Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2008

View Archived Issues

Santen patents novel HDAC inhibitors for glaucoma

Recent patents divulge novel analgesic agents

Novel agents for treating thrombosis disclosed in recent Wyeth patent

Clinical Data and Avalon enter into definitive merger agreement

Broad-spectrum antifungal activity seen with AN-2718 in vitro

Studies detail effects of prucalopride in chronic constipation, intestinal pseudo-obstruction

CombinatoRx provides data from phase IIb osteoarthritis study with Synavive

Chelsea completes enrollment in phase II clinical trial of CH-1504 in RA

Nycomed reports encouraging results from four phase III trials of Daxas in COPD

Provectus successfully completes phase I clinical trial of PV-10 in recurrent breast cancer

BioWa licenses Potelligent to KaloBios

Wakunaga identifies novel fluoroquinolone with activity against resistant respiratory bacteria

Cipher provides update on CIP-Tramadol ER regulatory filing

EMD Serono and Theratechnologies collaborate for tesamorelin in the U.S.

HealthLinx launches OvPlex ovarian cancer screening test in Australia

BioMimetic reports clinical results using Augment Injectable Bone Graft

Northfield Laboratories submits BLA to FDA for PolyHeme red cell substitute

Bristol-Myers Squibb presents studies of BMS-582949 in humans

Oral formulation of 17-AAG metabolite IPI-493 displays potency, in vivo activity

Phenomix initiates treatment in phase Ia clinical trial of protease inhibitor PHX-1766 in HCV

Phase I and other data on HDAC inhibitor SB-939 presented

Applied Biosystems stockholders approve proposed merger with Invitrogen

South Africa Medicines Control Council discontinues registration of Biopure's Hemopure

Anadys initiates dosing in phase Ib clinical trial of ANA-598 in HCV infection

FDA approves sanofi-aventis' Apidra insulin for diabetic children aged 4 years and older

ImClone Systems launches monoclonal antibody Erbitux in Canada for mCRC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...